RxDoctor Payments Data

Norman McNulty, MD

Neurology · Lawrenceburg, TNNPI 1013195452

Payments from drug & device makers

$1,635in general payments, 2019–2025

Across 108 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$256
  • SK Life Science, Inc.$254
  • Sumitomo Pharma America, Inc.$232
  • AbbVie$214
  • Sanofi$170
  • Lilly USA, LLC$160
  • plus $349 from 9 others

What the payments were for

  • Food & beverage$1,53894%
  • Education$966%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,635 in reported general payments places this provider in the 40th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$202,220
Medicare patients
414
Services billed
12,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$147,182
Aimovig AutoinjectorErenumab-Aooe163$128,833
AubagioTeriflunomide11$125,619
Teriflunomide44$120,683
Kesimpta PenOfatumumab13$111,325
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$106,033
BotoxOnabotulinumtoxina67$99,879
AptiomEslicarbazepine Acetate29$61,626
UbrelvyUbrogepant54$58,452
Emgality PenGalcanezumab-Gnlm67$52,300
QuliptaAtogepant41$46,463
NuedextaDextromethorphan Hbr/Quinidine17$25,583
EliquisApixaban37$24,057
XcopriCenobamate17$19,565
Nurtec OdtRimegepant Sulfate16$15,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$214$204,794162 claims
SanofiAubagio$170$125,61911 claims
Sunovion Pharmaceuticals Inc.Aptiom$46$61,62629 claims
PfizerEliquis, Nurtec Odt$14$39,74453 claims
Avanir Pharmaceuticals, Inc.Nuedexta$19$25,58317 claims
SK Life Science, Inc.Xcopri$254$19,56517 claims
Lilly USA, LLCReyvow$160$12,64517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 361 neurology providers in Tennessee.

Other neurology in Lawrenceburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →